145 related articles for article (PubMed ID: 19943049)
21. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
Colovic N; Tosic N; Aveic S; Djuric M; Milic N; Bumbasirevic V; Colovic M; Pavlovic S
Ann Hematol; 2007 Oct; 86(10):741-7. PubMed ID: 17579862
[TBL] [Abstract][Full Text] [Related]
22. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
[TBL] [Abstract][Full Text] [Related]
23. Low MDR1 and BAALC expression identifies a new subgroup of intermediate cytogenetic risk acute myeloid leukemia with a favorable outcome.
Guo X; Shi P; Chen F; Zha J; Liu B; Li R; Dong H; Zheng H; Xu B
Blood Cells Mol Dis; 2014 Sep; 53(3):144-8. PubMed ID: 24855032
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
[TBL] [Abstract][Full Text] [Related]
25. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.
Kim JS; Eom JI; Cheong JW; Choi AJ; Lee JK; Yang WI; Min YH
Clin Cancer Res; 2007 Feb; 13(3):1019-28. PubMed ID: 17289898
[TBL] [Abstract][Full Text] [Related]
26. High expression of costimulatory molecules correlates with low relapse-free survival probability in acute myeloid leukemia (AML).
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Kroell T; Pfister K; Schmetzer H
Ann Hematol; 2005 May; 84(5):287-97. PubMed ID: 15592672
[TBL] [Abstract][Full Text] [Related]
27. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.
Cilloni D; Renneville A; Hermitte F; Hills RK; Daly S; Jovanovic JV; Gottardi E; Fava M; Schnittger S; Weiss T; Izzo B; Nomdedeu J; van der Heijden A; van der Reijden BA; Jansen JH; van der Velden VH; Ommen H; Preudhomme C; Saglio G; Grimwade D
J Clin Oncol; 2009 Nov; 27(31):5195-201. PubMed ID: 19752335
[TBL] [Abstract][Full Text] [Related]
28. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
[TBL] [Abstract][Full Text] [Related]
29. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
31. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia.
Tamm I; Richter S; Oltersdorf D; Creutzig U; Harbott J; Scholz F; Karawajew L; Ludwig WD; Wuchter C
Clin Cancer Res; 2004 Jun; 10(11):3737-44. PubMed ID: 15173080
[TBL] [Abstract][Full Text] [Related]
32. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia.
Chen CC; Gau JP; You JY; Lee KD; Yu YB; Lu CH; Lin JT; Lan C; Lo WH; Liu JM; Yang CF
Am J Hematol; 2009 Feb; 84(2):87-92. PubMed ID: 19127593
[TBL] [Abstract][Full Text] [Related]
34. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances.
Mrózek K; Döhner H; Bloomfield CD
Curr Opin Hematol; 2007 Mar; 14(2):106-14. PubMed ID: 17255787
[TBL] [Abstract][Full Text] [Related]
35. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
36. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
[TBL] [Abstract][Full Text] [Related]
37. BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia.
Kornblau SM; Vu HT; Ruvolo P; Estrov Z; O'Brien S; Cortes J; Kantarjian H; Andreeff M; May WS
Clin Cancer Res; 2000 Apr; 6(4):1401-9. PubMed ID: 10778970
[TBL] [Abstract][Full Text] [Related]
38. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals.
Ommen HB; Nyvold CG; Braendstrup K; Andersen BL; Ommen IB; Hasle H; Hokland P; Ostergaard M
Br J Haematol; 2008 Jun; 141(6):782-91. PubMed ID: 18410450
[TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics.
Kornblau SM; Thall PF; Estrov Z; Walterscheid M; Patel S; Theriault A; Keating MJ; Kantarjian H; Estey E; Andreeff M
Clin Cancer Res; 1999 Jul; 5(7):1758-66. PubMed ID: 10430080
[TBL] [Abstract][Full Text] [Related]
40. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
